| Literature DB >> 32373529 |
Rebecca Levin-Epstein1, George Qiao-Guan2, Jesus E Juarez1, Zhouhuizi Shen1, Michael L Steinberg1, Dan Ruan1, Luca Valle1, Nicholas G Nickols1,3,4, Patrick A Kupelian1, Christopher R King1, Minsong Cao1, Amar U Kishan1,4.
Abstract
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiotherapy (SBRT) of prostate cancer based on inter- and intra-fractional prostate motion determined from daily image guidance. Methods and Materials: Two hundred and five patients who were enrolled on two prospective studies of SBRT (8 Gy × 5 fractions) for localized prostate cancer treated at a single institution between 2012 and 2017 had complete inter- and intra-fractional shift data available. All patients had scheduled kilovoltage planar imaging during SBRT with rigid registration to intraprostatic fiducials prior to each of four half-arcs delivered per fraction, as well as cone beam CT verification of anatomy prior to each fraction. Inter- and intra- fractional shift data were obtained to estimate the required PTV margins based on the classic van Herk formula. Inter- and intra-fractional motion were compared between patients with and without severe toxicities using the independent two-sample Wilcoxon test.Entities:
Keywords: SBRT; image-guidance; margins; planning target volume; prostate cancer; prostate motion; stereotactic body radiation therapy
Year: 2020 PMID: 32373529 PMCID: PMC7177009 DOI: 10.3389/fonc.2020.00539
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Our image-guided work flow during the treatment of stereotactic body radiation therapy for prostate cancer. Initially, patient positioning is accomplished by orthogonal image pair or stereoscopic X-ray imaging with ExacTrac® and cone-beam computed tomography (CBCT) before treatment beam-on. Repeat orthogonal image pair or stereoscopic X-ray imaging is obtained prior to each beam delivery (each of three remaining half-arcs) to account for intra-fractional motion. Each half-arc is delivered over ~2–3 min.
Patient characteristics.
| Total participants (n) | 205 |
| Median age, (range), in years | 70 (44–87) |
| Median clinical target volume, (range), [interquartile range], in cubic centimeters (cc) | 58.7 cc (46.4–75.4 cc) [23.8–154.3 cc] |
| Median initial PSA, (range) | 6.9 ng/mL (0.05–70 ng/mL) |
| Distribution of T stage (%) | |
| cT1c | 72.5% |
| cT2a | 19.4% |
| cT2b | 3.3% |
| cT2C | 1.4% |
| cT3a | 1.9% |
| cT3b | 0.5% |
Mean, standard deviation (SD, Σ), and root mean square (RMS, σ) of inter- and intra- fractional motion of the prostate for patients treated with 5-fraction stereotactic body radiation therapy.
| −0.03 | −0.06 | −0.06 | 0.07 | 0.13 | 0.14 | |
| 0.30 | 0.43 | 0.45 | 0.05 | 0.07 | 0.09 | |
| 0.35 | 0.63 | 0.47 | 0.09 | 0.12 | 0.13 | |
| 0.99 | 1.52 | 1.45 | 0.19 | 0.27 | 0.31 | |
Calculated inter- and intra-fractional planning target volume margins required for prostate stereotactic body radiation therapy are presented. Inter-fractional margins reflect expansions that would be required if no inter-fractional image guidance were employed.
Figure 2Histogram demonstrating frequency of mean intra-fractional target displacement in the lateral (LR), longitudinal (SI), and vertical (AP) directions for all patients, as measured by three sets of intra-fractional orthogonal imaging.
Figure 3Mean implemented shifts for prostate displacement sequentially over the phases of treatment: from cone beam computed tomography (CBCT) to planar imaging just prior to initiation of arc 1, and between each of the partial arcs incorporating the displacement detected on the image pair obtained subsequent to the corresponding arc. Depicted mean shifts are relative to the immediate predecessor intra-fractional displacement and are based on an institutional threshold of implementing shifts with displacement ≥1 mm. Arc 4 is not included, as there is no IGRT performed after completion of the fourth arc delivery.
Mean inter- and intra-fractional prostate displacement (in cm) for patients with vs. without development of severe toxicity.
| −0.03 ± 0.30 | −0.06 ± 0.43 | −0.06 ± 0.45 | 0.07 ± 0.05 | 0.13 ± 0.07 | 0.14 ± 0.09 | |
| 0.02 ± 0.16 | 0.03 ± 0.37 | 0.07 ± 0.41 | 0.07 ± 0.03 | 0.14 ± 0.07 | 0.08 ± 0.06 | |
| 0.99 | 0.98 | 0.46 | 0.80 | 0.84 | 0.10 | |